Apollo Endosurgery, Inc.: management transactions · United States · SEC (Form 4)

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. was a U.S. medical device company focused on therapeutic endoscopy and minimally invasive gastrointestinal procedures. Founded in 2005, the company was headquartered in Austin, Texas, United States, and it traded on the NASDAQ under the ticker APEN prior to its acquisition. Its business model centered on a specialist niche: enabling gastroenterologists and surgeons to treat digestive disorders through less invasive technologies, especially for gastrointestinal defect closure, management of GI complications, and obesity treatment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1251769/000125176917000013/form10k.htm?utm_source=openai)) The company’s core franchise was built around a recognized set of endobariatric and interventional endoscopy platforms, including the OverStitch Endoscopic Suturing System, OverStitch Sx, X-Tack Endoscopic HeliX Tacking System, and the ORBERA Intragastric Balloon. Apollo also expanded into related systems such as Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx, broadening its reach into endoscopic sleeve gastroplasty and revision procedures. This portfolio placed Apollo in a high-barrier segment where clinical adoption depends on physician training, clinical evidence, reimbursement dynamics, and ongoing indication expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1251769/000125176922000071/R23.htm?utm_source=openai)) From a competitive standpoint, Apollo Endosurgery was a focused specialty player rather than a broad-based medtech conglomerate. Its differentiation came from technical know-how in therapeutic GI endoscopy and from an integrated offering spanning suturing, tissue approximation, bariatric therapy, and defect management. Apollo stated that its products were offered in more than 75 countries, underscoring a meaningful international footprint beyond the U.S. market. For investors, however, the key point is that Apollo Endosurgery is no longer an independent listed company: Boston Scientific completed its acquisition of 100% of Apollo on April 4, 2023, and the Apollo portfolio was integrated into Boston Scientific’s Endoscopy division. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1251769/000125176920000075/ex99-1pressrelease.htm?utm_source=openai)) Recent corporate developments are therefore dominated by the takeover process. Boston Scientific announced the all-cash acquisition agreement in November 2022 at an enterprise value of approximately $615 million, and the transaction closed in April 2023. Since then, Apollo’s technologies have been reported as part of Boston Scientific’s endoscopy portfolio, which improves commercial reach and strategic scale while ending Apollo’s standalone equity story on NASDAQ. For an SEC Form 4 context, Apollo should be treated as a former issuer that has been absorbed into a larger U.S. listed medtech platform rather than an active independent public company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1251769/000119312522293871/d417943ddefa14a.htm?utm_source=openai))